Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,678,610
  • Shares Outstanding, K 111,982
  • Annual Sales, $ 605,220 K
  • Annual Income, $ -168,630 K
  • EBIT $ -177 M
  • EBITDA $ -191 M
  • 60-Month Beta 0.73
  • Price/Sales 2.58
  • Price/Cash Flow N/A
  • Price/Book 3.85

Options Overview Details

View History
  • Implied Volatility 110.50% (-8.73%)
  • Historical Volatility 114.21%
  • IV Percentile 93%
  • IV Rank 63.42%
  • IV High 146.13% on 02/13/26
  • IV Low 48.72% on 06/06/25
  • Expected Move (DTE 22) 2.42 (17.62%)
  • Put/Call Vol Ratio 0.39
  • Today's Volume 2,730
  • Volume Avg (30-Day) 1,922
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 39,185
  • Open Int (30-Day) 27,438
  • Expected Range 11.33 to 16.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.41
  • Number of Estimates 4
  • High Estimate -0.30
  • Low Estimate -0.47
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +32.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.82 +40.02%
on 02/09/26
15.46 -11.06%
on 02/25/26
+0.49 (+3.70%)
since 01/26/26
3-Month
9.82 +40.02%
on 02/09/26
15.46 -11.06%
on 02/25/26
+0.99 (+7.76%)
since 11/26/25
52-Week
9.82 +40.02%
on 02/09/26
21.55 -36.19%
on 03/12/25
-8.21 (-37.39%)
since 02/26/25

Most Recent Stories

More News
NovoCure: Q4 Earnings Snapshot

NovoCure: Q4 Earnings Snapshot

NVCR : 13.75 (-8.27%)
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax ® approved by the U.S. FDA for the...

NVCR : 13.75 (-8.27%)
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

British Columbia becomes first Canadian province to provide coverage for TTFields therapy for eligible glioblastoma patients

NVCR : 13.75 (-8.27%)
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3...

NVCR : 13.75 (-8.27%)
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Novocure to present at the 44 th Annual...

NVCR : 13.75 (-8.27%)
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that management will participate in the 44 th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank...

NVCR : 13.75 (-8.27%)
Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley...

NVCR : 13.75 (-8.27%)
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that management will participate in the 37 th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle,...

NVCR : 13.75 (-8.27%)
Novocure to Participate in 2025 Jefferies Global Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer,...

NVCR : 13.75 (-8.27%)
NovoCure: Q3 Earnings Snapshot

NovoCure: Q3 Earnings Snapshot

NVCR : 13.75 (-8.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 16.67
2nd Resistance Point 15.30
1st Resistance Point 14.53
Last Price 13.75
1st Support Level 12.39
2nd Support Level 11.02
3rd Support Level 10.25

See More

52-Week High 21.55
Fibonacci 61.8% 17.07
Fibonacci 50% 15.68
Fibonacci 38.2% 14.30
Last Price 13.75
52-Week Low 9.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar